ECHO-306/KEYNOTE-715 assessed epacadostat 100 mg BID plus pembrolizumab with chemotherapy in NSCLC [24]; however, enrollment did not require PD-L1 TPS ≥ 50%. Here, CD274 is linked to non-small cell lung carcinoma.